Abstract: SA-OR10
Recovery from AKI and Acute Respiratory Distress Syndrome (ARDS) with the Use of Low-Dose Steroids During COVID-19 Infection in an African American Population: A Retrospective Analysis
Session Information
- Coronavirus: Research Abstracts
October 24, 2020 | Location: Simulive
Abstract Time: 05:00 PM - 07:00 PM
Category: Coronavirus (COVID-19)
- 000 Coronavirus (COVID-19)
Authors
- Saggi, Subodh J., SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Nath, Sridesh, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Culas, Roshni, Saint Barnabas Hospital, Bronx, New York, United States
- Chittalae, Seema, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Burza, Aaliya, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Geraghty, Patrick, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Ouyang, Jie, SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Gruessner, Angelika C., SUNY Downstate Health Sciences University, Brooklyn, New York, United States
- Salifu, Moro O., SUNY Downstate Health Sciences University, Brooklyn, New York, United States
Background
Corona Virus Disease-19 (CoVID-19) infection associated with AKI and ARDS results in a mortality of 80%. In AA population COVID 19 presentations and outcomes are worse. NIH and Interim WHO guidelines suggest against steroids use unless in the context of clinical trials. We conducted a retrospective analysis on the impact of 2 different doses of IV steroids in AA adult population.
Methods
75 patients between March 1 and April 30, 2020 were enrolled. Primary outcomes (21-day mortality) and secondary outcomes (improvement in lung function and renal function) were analyzed. Comparisons between the steroid doses (methylprednisolone 1 mg/kg/day or 2 mg/kg/day) and no-steroid groups were performed with the Wilcoxon, Kruskal-Wallis, and Chi-Square tests. Factors affecting the recovery of AKI or ARDS were analyzed. AKI recovery was defined as 50% increase of GFR, and cessation of RRT; lung function recovery was defined as improved oxygenation by P/F ratio > 200 and extubation.
Results
38 out 75 patients received steroids. Survival in the steroids group reached 73% at 21 days compared to 36% in the non-steroids group (p<0.0006). Steroids improved the likelihood of renal function improvement by 300% (p=0.06). Lung functionwas 73% in the steroids group versus 45% in the other (p=0.01). Use of anticoagulants (16% vs 51%, p= 0.001) seemed to be interacting with steroids on outcomes. Low dose steroids had the most beneficial impact.
Conclusion
In patients with COVID-19 infection and ARDS with AKI, low dose IV methylprednisolone was associated with a significantly lower incidence of mortality and higher likelihood of renal and lung function recovery. Further investigation with a randomized control trial consisting of low dose steroids seems warranted.
Mortality in stroids and non-steroids groups